Quantifying the Long-Run Economic and Health Impact of Reduced Intellectual Property Protections for New Drugs

That is the title of a new working paper written by myself, any my FTI Consulting colleagues Sabiha Quddus and Suhail Thahir. The abstract is below. Some policymakers have called for weakening of intellectual property protections for vaccines and other pharmaceutical products, with the aim to reduce the price and improve access to existing medical…

Complexities of COVID-19 manufacturing

Getting from a mRNA COVID-19 vaccine to scaling to manufacture these vaccines for billions of people is far from simple: Manufacturing mRNA vaccines for the first time in a very short timeframe required significant innovation and remains a technically challenging endeavor. The process proved to be technically challenging as Pfizer developed a 50,000 step process.…